Tivicay (Dolutegravir) for HIV

Overview
Tivicay is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in combination with other antiretroviral medications. Tivicay is also referred to by its drug name, Dolutegravir, and by the abbreviation DTG. Dolutegravir is a component in the combination drug Triumeq. Tivicay is an antiviral medication of the integrase strand transfer inhibitor (INSTI) class. Tivicay is believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Tivicay is taken once or twice daily. Tivicay comes in tablet form.

Side effects
The FDA-approved label for Tivicay lists common side effects including headache, insomnia, fatigue, and changes in the shape or location of body fat. Rare but serious side effects listed for Tivicay include severe hypersensitivity reactions and worsening of hepatitis B or C infections.

For more details about this treatment, visit:

Tivicay.com

Overview of HIV Treatments – AIDS.gov